Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States

INTRODUCTION: Lenvatinib has become the most commonly prescribed first-line (1L) agent for the treatment of radioactive iodine-refractory differentiated thyroid cancer (RAI-r DTC) since its approval in 2015. With no real-world studies describing clinical outcomes of 1L lenvatinib and subsequent ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kish, Jonathan K., Chatterjee, Debanjana, Wan, Yin, Yu, Hsing-Ting, Liassou, Djibril, Feinberg, Bruce A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467445/
https://www.ncbi.nlm.nih.gov/pubmed/32382946
http://dx.doi.org/10.1007/s12325-020-01362-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467445/
https://www.ncbi.nlm.nih.gov/pubmed/32382946
http://dx.doi.org/10.1007/s12325-020-01362-6

Ejemplares similares